公开(公告)号：WO2017079622A1

公开(公告)日：2017-05-11

申请号：PCT/US2016/060627

申请日：2016-11-04

Applicant: EMORY UNIVERSITY ,  ST. JUDE CHILDREN'S HOSPITAL, INC.

Inventor： AHMED, Rafi ,  YOUNGBLOOD, Benjamin

IPC: C12N5/071 ,  C12N5/10 ,  C12N15/00

CPC classification number: C12N5/10 ,  C12N9/1007 ,  C12Y201/01037

Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.

Abstract translation: 本公开涉及免疫细胞中DNMT3A基因的遗传修饰。 在某些实施方案中，修饰的免疫细胞可用于过继性T细胞疗法以增强针对癌症或慢性感染的免疫应答。 在某些实施方案中，本公开内容涉及在免疫细胞例如人CD8T细胞中删除，改变或插入DNMT3A基因内的核苷酸，使得DNMT3A基因产物不用于甲基化。 在某些实施方案中，DNMT3A基因的修饰提供了抗原特异性T细胞功能的改善和/或细胞寿命的提高。

公开(公告)号：WO2008070858A1

公开(公告)日：2008-06-12

申请号：PCT/US2007/086854

申请日：2007-12-07

Applicant: UNIVERSITY OF CHICAGO ,  GODLEY, Lucy, A. ,  OSTLER, Kelly, R.

Inventor： GODLEY, Lucy, A. ,  OSTLER, Kelly, R.

IPC: A61K38/16 ,  A61P35/00

CPC classification number: A61K38/45 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/14 ,  C12Y201/01037

Abstract: The present invention provides new methods of inhibiting aberrant DNA methyltransferase 3B (DNMT3B) transcripts containing abnormal splicing. Inhibitory nucleic acids, such as interfering RNAs and antisense molecules target improperly retained introns, thereby selectively inhibiting aberrant transcripts. Methods of treating cancers that involve aberrant DNMT3B transcripts also are provided.

Abstract translation: 本发明提供抑制含有异常剪接的异常DNA甲基转移酶3B（DNMT3B）转录物的新方法。 抑制性核酸，例如干扰RNA和反义分子靶向不正确保留的内含子，从而选择性抑制异常转录物。 还提供了治疗涉及异常DNMT3B转录物的癌症的方法。

公开(公告)号：WO2018142416A1

公开(公告)日：2018-08-09

申请号：PCT/IL2018/050134

申请日：2018-02-06

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： SOREK, Rotem ,  SBERRO, Hila ,  OFIR, Gal ,  MELAMED, Sarah

IPC: C07K14/195 ,  C12N9/10 ,  C12N1/20

CPC classification number: C12Y306/04013 ,  A61P31/04 ,  C07K14/195 ,  C07K14/32 ,  C12N1/20 ,  C12N9/1007 ,  C12N15/52 ,  C12Y201/01037 ,  C12Y306/04012

Abstract: Isolated cells genetically modified to express a DISRAM system are provided. Accordingly there is provided an isolated cell genetically modified to express a DISARM system having an anti-phage activity, the system comprising a drmM polypeptide; a drmA polypeptide; a drmB polypeptide; and a drmD polypeptide or a drmE polypeptide. Also provided are compositions and methods for conferring phage resistance to bacteria or for conferring bacterial susceptibility to phages.

公开(公告)号：WO2016085944A1

公开(公告)日：2016-06-02

申请号：PCT/US2015/062352

申请日：2015-11-24

Applicant: CASE WESTERN RESERVE UNIVERSITY

Inventor： KHALIL, Ahmad ,  MARKOWITZ, Sanford

IPC: A61K31/7105

CPC classification number: C12N15/1137 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  C12N15/113 ,  C12N2310/10 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/11 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/178 ,  C12Y201/01037 ,  G01N33/50 ,  G01N33/574

Abstract: A method for treating cancer in a subject in need thereof includes administering to cancer cells of the subject an agent effective to modulate the level of DNMT1-associated RNA and/or the interaction of DNMT1-associated RNA and DNMT1 in the cancer cells of the subject. Embodiments described herein relate to RNAs (e.g., IncRNAs) associated with DNA methyltransferase 1 (DNMTI-associcated RNA) in human cancer cells, methods and compositions of modulating the levels of DNMTI-associcated RNA and/or the interaction of DNMT1-associated RNA and DNMT1 in cancer cells of the subject to treat cancer cells or a subject in need thereof, and/or methods of measuring the expression profile of DNMT1 associcated RNA to determine whether the subject has cancer or an increased risk of cancer and/or the efficacy of a therapeutic regimen agent.

Abstract translation: 在有需要的受试者中治疗癌症的方法包括向受试者的癌细胞施用有效调节DNMT1相关RNA水平和/或DNMT1相关RNA和DNMT1在受试者的癌细胞中的相互作用的试剂 。 本文描述的实施方案涉及与人类癌细胞中的DNA甲基转移酶1（DNMTI相关RNA）相关的RNA（例如，IncRNA），调节DNMTI相关RNA水平和/或DNMT1相关RNA与 DNMT1在受试者的癌细胞中以治疗癌细胞或需要其的对象，和/或测量DNMT1相关RNA的表达谱的方法，以确定受试者是否具有癌症或增加的癌症风险和/或其功效 治疗方案药物。

公开(公告)号：EP4437092A1

公开(公告)日：2024-10-02

申请号：EP22834472.7

申请日：2022-11-25

Applicant: Epigenic Therapeutics Inc.

Inventor： ZHOU, Changyang ,  SUN, Yidi ,  PENG, Wenbo ,  MAO, Shaoshuai

IPC: C12N9/22 ,  A61K38/00 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  C12N9/64 ,  C12N15/113

CPC classification number: C12N9/22 ,  C12Y304/21 ,  C12N9/6424 ,  C07K2319/8120130101 ,  C12N15/1137 ,  C12Y201/01037 ,  C12Y201/01072 ,  C12Y201/01113 ,  C07K2319/0020130101 ,  A61P3/06 ,  A61P9/10 ,  A61P3/10 ,  C07K2319/7120130101 ,  C12N2310/2020170501 ,  A61K38/45

公开(公告)号：EP3237017A4

公开(公告)日：2018-08-01

申请号：EP15872084

申请日：2015-12-24

Applicant: DANA FARBER CANCER INST INC ,  UNIV JOHNS HOPKINS

Inventor： NOVINA CARL ,  MEISTER GLENNA ,  OSTERMEIER MARC ,  XIONG TINA

IPC: A61K48/00 ,  C12N15/85

CPC classification number: C12N9/1007 ,  A61K48/00 ,  C07K2319/09 ,  C07K2319/80 ,  C07K2319/81 ,  C12N9/22 ,  C12N15/11 ,  C12N15/85 ,  C12N15/907 ,  C12N2310/20 ,  C12N2800/24 ,  C12N2800/40 ,  C12Q1/6897 ,  C12Q2600/154 ,  C12Y201/01 ,  C12Y201/01037 ,  C12Y301/00

Abstract: The present invention provides methods of systems and methods of site specific methylation.

公开(公告)号：EP3180348A4

公开(公告)日：2018-02-07

申请号：EP15829322

申请日：2015-08-08

Applicant: BAYLOR COLLEGE MEDICINE

Inventor： RAU RACHEL ,  GOODELL MARGARET A

IPC: C07H19/16 ,  A61K31/00 ,  A61K31/519 ,  A61K31/52 ,  C12Q1/48 ,  C12Q1/68

CPC classification number: C12Q1/6886 ,  A61K31/00 ,  A61K31/519 ,  A61K31/52 ,  C07H19/16 ,  C12Q2600/106 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Y201/01037

Abstract: The present disclosure relates to methods of treating AML, associated with DNMT3A mutations by administering one or more DOT1L inhibitors or related pharmaceutical compositions to subjects in need thereof.

公开(公告)号：US20240279623A1

公开(公告)日：2024-08-22

申请号：US18444590

申请日：2024-02-16

Applicant: Whitehead Institute for Biomedical Research

Inventor： Edwin Neumann ,  Tessa Bertozzi ,  Jonathan Weissman

IPC: C12N9/10 ,  A61K38/46 ,  C12N9/22 ,  C12N15/86

CPC classification number: C12N9/1007 ,  A61K38/465 ,  C12N9/22 ,  C12N15/86 ,  C12Y201/01037 ,  C07K2319/80 ,  C12N2750/14143

Abstract: The disclosure provides, in various embodiments, fusion proteins comprising a DNA-binding domain, a DNMT3A-binding domain, and a H3K4me0; and polynucleotides and vectors encoding one or more of the fusion proteins. The disclosure also provides, in various embodiments, gene-delivery systems, cells, compositions (e.g., pharmaceutical compositions) and kits comprising one or more of the fusion proteins polynucleotides, or vectors; methods of epigenetically modifying a genomic locus in a cell; and methods of treating a subject (e.g., a human) in need thereof.

公开(公告)号：US20240132855A1

公开(公告)日：2024-04-25

申请号：US18473990

申请日：2023-09-25

Applicant: Chroma Medicine, Inc.

Inventor： Aron Brandon Jaffe ,  Noorussahar Abubucker ,  Yesseinia Anglero-Rodriguez ,  Vic Myer ,  Angelo Leone Lombardo ,  Martino Alfredo Cappelluti

IPC: C12N7/00 ,  C07K14/47 ,  C12N9/10 ,  C12N9/22 ,  C12N15/11

CPC classification number: C12N7/00 ,  C07K14/4703 ,  C12N9/1007 ,  C12N9/22 ,  C12N15/11 ,  C07K2319/09 ,  C12N2310/20 ,  C12N2710/00021 ,  C12Y201/01037

Abstract: This invention relates to compositions, methods, strategies, and treatment modalities related to the epigenetic modification of hepatitis B virus (HBV) genes.

公开(公告)号：US20240123089A1

公开(公告)日：2024-04-18

申请号：US18516840

申请日：2023-11-21

Applicant: Scribe Therapeutics Inc.

Inventor： Jason FERNANDES ,  Sean HIGGINS ,  Sarah DENNY ,  Ross WHITE ,  Emeric Jean Marius CHARLES ,  Addison WRIGHT ,  Benjamin DEMAREE ,  Manuel MOHR ,  Wenyuan ZHOU ,  Benjamin OAKES

IPC: A61K48/00 ,  C12N9/10 ,  C12N9/22 ,  C12N15/113 ,  C12N15/88 ,  C12N15/90

CPC classification number: A61K48/005 ,  C12N9/1007 ,  C12N9/22 ,  C12N15/1137 ,  C12N15/88 ,  C12N15/907 ,  C12Y201/01037 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/531

Abstract: Provided herein are gene repressor systems comprising fusion proteins, such as fusion proteins comprising a DNA binding domain such as a TALE, zinc finger or catalytically-dead CRISPR protein and guide nucleic acid (gRNA), which are useful in the repression of a proprotein convertase subtilisin kexin Type 9 (PCSK9) gene. Also provided are methods of using such systems to repress transcription of PCSK9.